Trista Morrison - Swedish Orphan Insider

Swedish Orphan Biovitrum AB -- USA Stock  

USD 14.72  0.0005  0.0034%

Vice President - Communications for North America

Ms. Trista Morrison is Vice President Communications for North America of the Company. Morrison more than 15 years in biopharmaceutical communications span corporate, reporter and agency roles. Most recently, Morrison served as director of corporate communications for Ironwood Pharmaceuticals, where she led internal, external and brand communications as the company transitioned from a research and development organization to a fully integrated commercial biotechnology company. Prior to her role at Ironwood, Morrison served as an editor and staff writer at BioWorld Today, covering breaking news and trends in the biopharmaceutical industry. Previously she served in various positions with biopharmaceuticalfocused public relations agency Porter Novelli Life Sciences . Morrison was honored as one of PR News Top Women in PR in 2017, which recognizes communicators who have made bold advances in the profession.
  President Since 2017      
46 86 97 20 00  http://www.sobi.com

Management Efficiency

The company has return on total asset (ROA) of 6.58 % which means that it generated profit of $6.58 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 14.88 % meaning that it generated $14.88 on every $100 dollars invested by stockholders.
The company has accumulated 60.96 M in total debt with debt to equity ratio (D/E) of 7.9 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Swedish Orphan Biovitrum AB has Current Ratio of 1.78 which is within standard range for the sector.

Similar Executives

Showing few of many executives

PRESIDENT Since

Craig FederighiApple Inc
2012
Phil SchillerApple Inc
2002
Karim GarciaMetro Pacific Investments Corpo
2015
Reymundo CochangcoMetro Pacific Investments Corpo
2010
Loudette ZoiloMetro Pacific Investments Corpo
2012
Maricris AldoverYsmaelMetro Pacific Investments Corpo
2016
Albert PulidoMetro Pacific Investments Corpo
2009
Ferdinand InacayMetro Pacific Investments Corpo
2010
Johny SroujiApple Inc
2015
Katherine AdamsApple Inc
2017
Robin VelascoMetro Pacific Investments Corpo
2009
Celso LopezMetro Pacific Investments Corpo
2014
Melody RosarioMetro Pacific Investments Corpo
2009
Bruce SewellApple Inc
2009
Dan RiccioApple Inc
2012
Ricardo PilaresMetro Pacific Investments Corpo
2015
Santhea SantosMetro Pacific Investments Corpo
2014
Philip SchillerApple Inc
1997
Durward SewellApple Inc
2009
Eddy CueApple Inc
2011
Sergey BrinAlphabet Inc
2015

Entity Summary

Swedish Orphan Biovitrum AB , an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Europe and North America. Swedish Orphan Biovitrum AB (BIOVF) is traded on OTC Market in USA. It is located in Stockholm, and employs 758 people.
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add Swedish Orphan Biovitrum AB to your portfolio

Top Management

Swedish Orphan Biovi Leadership Team
Hans Wigzell, Director, Ph.D
Lennart Johansson, Director, MBA
Annette Clancy, Director
Trista Morrison, President
Kirsti Gjellan, President
Jorgen Winroth, VP
Milan Zdravkovic, President, Ph.D
Hans Schikan, Director
Dennis Pedersen, President
Helena Saxon, Director, MBA
Anders Edvell, Executive, MBA
Geoffrey McDonough, CEO, Ph.D
Lars Dreioee, President, MBA
Alan Raffensperger, COO
Fredrik Berg, Executive
BoGunnar Rosenbrand, Director
Adine Axen, Director
Birgitte Volck, President
MatsOlof Wallin, President
Stefan Fraenkel, President, MBA
Hakan Bjorklund, Chairman, Ph.D
Cecilia Forberg, President
Stephen James, President, Ph.D
Bo Hansen, Chairman, Ph.D
Armin Reininger, President, Ph.D
Catarina Larsson, Director
Wills HughesWilson, President
Guido Oelkers, CEO
Jeffrey Jonas, Director, Ph.D
Matthew Gantz, Director, MBA
Theresa Heggie, Director

Stock Performance

Swedish Orphan Performance Indicators